MARKET

VIVE

VIVE

Viveve Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.450
+0.040
+1.66%
After Hours: 2.490 +0.04 +1.63% 18:25 05/17 EDT
OPEN
2.430
PREV CLOSE
2.410
HIGH
2.520
LOW
2.430
VOLUME
54.21K
TURNOVER
--
52 WEEK HIGH
14.40
52 WEEK LOW
2.400
MARKET CAP
33.78M
P/E (TTM)
-0.1273
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 3d ago
BRIEF-Viveve Medical Posts Quarterly Loss Per Share Of $0.80
reuters.com · 4d ago
Recap: Viveve Medical Q1 Earnings
Shares of Viveve Medical (NASDAQ:VIVE) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 2.44% year over year to ($0.80), which missed the estimate of ($0.51).
Benzinga · 4d ago
Viveve Medical EPS misses by $0.29, beats on revenue
Viveve Medical (VIVE): Q1 GAAP EPS of -$0.80 misses by $0.29.Revenue of $1.45M (+11.5% Y/Y) beats by $0.12M.Shares +0.8%.Press Release
Seekingalpha · 4d ago
Viveve Medical Q1 EPS $(0.80) Misses $(0.51) Estimate, Sales $1.50M Beat $1.33M Estimate
Viveve Medical (NASDAQ:VIVE) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.51) by 56.86 percent. This is a 2.44 percent increase over losses of $(0.82) per share from
Benzinga · 4d ago
Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update
ACCESSWIRE · 4d ago
-- Earnings Flash (VIVE) VIVEVE MEDICAL Reports Q1 Revenue $1.5M, vs. Street Est of $1.33M
MT Newswires · 4d ago
Earnings Scheduled For May 13, 2021
  Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Benzinga · 4d ago
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VIVE. Analyze the recent business situations of Viveve Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VIVE stock price target is 9.63 with a high estimate of 10.75 and a low estimate of 8.50.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 17.88M
% Owned: 129.69%
Shares Outstanding: 13.79M
TypeInstitutionsShares
Increased
4
364.97K
New
4
95.10K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-0.90%
Healthcare Equipment & Supplies
-0.70%
Key Executives
Chairman/Independent Director
Steven Basta
Chief Executive Officer/Director
Scott Durbin
Chief Financial Officer/Vice President - Finance
Jim Robbins
Vice President
Sean Shapiro
Director
Debora Jorn
Director
Deborah Jorn
Independent Director
Arlene Morris
Independent Director
Sharon Presnell
No Data
About VIVE
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.

Webull offers kinds of Viveve Medical Inc stock information, including NASDAQ:VIVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIVE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIVE stock methods without spending real money on the virtual paper trading platform.